mTOR-inhibiting medicine · Fact sheet

Sirolimus

Also known as rapamycin · Rapamune

Sirolimus is FDA approved for specific transplant and lymphangioleiomyomatosis uses—not to slow aging or extend life. Small healthy-aging trials are exploratory, while approved labeling documents major infection, malignancy, metabolic, lung, wound-healing, and interaction risks.

FDA approved for specific usesStrong human evidence for approved uses

What is Sirolimus?

Sirolimus is a macrolide medicine that inhibits mTOR, a signaling pathway involved in growth, nutrient sensing, immunity, and cell maintenance.

Rapamycin extends lifespan in several animal models, but translating that finding to healthy humans requires outcomes trials and careful safety testing.

Benefits & claims

mTOR is a central geroscience target, making sirolimus one of the most discussed drug-repurposing candidates in longevity research.

The same immune and growth pathways that make it scientifically interesting also explain why benefits cannot be considered separately from risk.

What the evidence supports

  • Small aging trials suggest that controlled research is feasible and have reported selected exploratory signals.
  • The PEARL trial did not establish a general longevity benefit and its primary visceral-fat outcome was not significantly improved overall.
Research areas
  • Organ-transplant immunosuppression
  • Lymphangioleiomyomatosis
  • Immune aging and vaccine response
  • Physical function and biological-aging measures

Dosage & frequency

Product-specific label information

Rapamune has monitored transplant and lymphangioleiomyomatosis regimens. These do not establish an intermittent anti-aging schedule.

Rapamune: lymphangioleiomyomatosis

Patients with lymphangioleiomyomatosis

Amount
2 mg starting daily amount; adjusted to whole-blood trough concentrations 5–15 ng/mL
Frequency
Once daily
Route studied or labeled
Oral

Therapeutic drug monitoring; not a transplant or longevity schedule.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Whole-blood trough monitoring is part of approved clinical use.

Interactions & precautions

  • CYP3A4/P-gp inhibitors or inducers, grapefruit, and cyclosporine can substantially alter sirolimus exposure.

What is still unresolved

  • A longevity regimen with a favorable long-term benefit–risk balance remains unestablished.

Side effects & risks

  • Approved labeling carries boxed warnings and describes increased susceptibility to infection and possible development of malignancies.
  • Other important risks include high cholesterol and triglycerides, impaired wound healing, mouth inflammation, blood-cell changes, lung toxicity, kidney-related concerns, and extensive drug interactions.
  • Risk in closely monitored transplant or rare-disease care cannot be assumed acceptable for a healthy person seeking longevity.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Evidence is strong for labeled medical uses, where monitoring and risk management are part of care. Healthy-aging evidence consists of small feasibility and exploratory trials without proof of longer life or prevention of age-related disease.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Brief improvement followed by persistent symptoms

An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.

Reported use in this account

Product
Product labeled rapamycin
Amount
1 mg initially; later 2 mg, as reported
Frequency
Weekly
Route
Not specified clearly
Duration
About six weeks before stopping

Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.

Read the original account

Approval status

FDA-approved sirolimus products have specific indications, including prevention of organ rejection in selected kidney-transplant patients and treatment of lymphangioleiomyomatosis. Aging and longevity are not approved indications.

Approved uses

  • Specific transplant and lymphangioleiomyomatosis uses described in current FDA-approved labeling

FDA approved for non-aging indications

Sirolimus is FDA approved under Rapamune labeling for defined medical uses. Healthy-aging or longevity use remains investigational and should not be folded into the approval.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether sirolimus can extend healthy human lifespan
  • Whether any aging-related benefit outweighs immune, metabolic, and other harms
  • Which biomarkers are meaningful rather than merely responsive
  • Long-term outcomes in healthy or near-healthy populations

Summary

Sirolimus has approved uses and serious labeled risks. Longevity benefits in healthy people remain unproven.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Rapamune

    Official indications, boxed warnings, contraindications, adverse reactions, and interactions.

  2. pubmedPEARL randomized trial of sirolimus in healthy aging

    Exploratory controlled trial that did not prove longevity or broad healthspan benefit.

  3. pubmedPilot sirolimus study in older adults

    Small randomized study focused on feasibility and selected physiological outcomes.

  4. nihRapamune current prescribing information

    Primary source for the practical reference information.

How we assess sources · Suggest a correction